Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002327779 | SCV002627061 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-01-14 | criteria provided, single submitter | clinical testing | The c.419_420insAlu pathogenic mutation results from an Alu element insertion at nucleotide positions 419 to 420 in coding exon 5 of the PTEN gene. Alu element insertions contribute to pathogenicity by either disrupting the coding sequence or inducing aberrant splicing (Belancio VP et al. Semin. Cancer Biol. 2010 Aug;20:200-10; Deininger P et al. Genome Biol. 2011 Dec;12:236). In one study, similar Alu element insertions with different breakpoints (c.437_438) in coding exon 5 of PTEN were reported in two unrelated probands that met clinical diagnostic criteria for PTEN hamartoma tumor syndrome, one of whom had two affected children that also tested positive for the variant (Crivelli L et al. Eur J Hum Genet, 2017 09;25:1087-1091). In addition, analysis of patient RNA by RT-PCR identified aberrant splicing associated with the variant resulting in exon 5 skipping, which is predicted to lead to a translational frameshift (Crivelli L et al. Eur J Hum Genet, 2017 09;25:1087-1091). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |